Antitumor activity was modest overall (ORR 12.1%), while ORR at the recommended phase 2 dose was 21.1% with only 5.3% primary progression versus 33.7% previously reported. Efficacy signals were ...

Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

Time to first symptomatic skeletal event, whether including or excluding death, was similar between treatment arms. Most patients did not experience skeletal complications during the follow-up period.

The phase 3 IMvigor011 (NCT04660344) 1 trial, presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, represents a landmark shift toward perso ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...